Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial DNABII family proteins, primarily comprising Integration Host Factor (IHF) and Histone-like protein (HU), are small, basic, DNA-binding proteins that are essential for the structural integrity of bacterial biofilms (Goodman et al., 2011, PubMed: 21613501). While traditionally known for their intracellular roles in nucleoid organization and gene regulation, these proteins are also secreted into the extracellular polymeric substance (EPS) of biofilms. There, they bind to and stabilize the junctions of extracellular DNA (eDNA) lattices, acting as critical 'linchpins' that maintain the three-dimensional architecture of the biofilm (Devaraj et al., 2015, PubMed: 25938842). This structural role protects the resident bacteria from environmental stressors, host immune defenses, and antibiotic penetration, contributing to the chronic nature of many bacterial infections. Targeting DNABII proteins represents a novel therapeutic strategy to combat biofilm-mediated resistance. Monoclonal antibodies, such as the clinical-stage candidate TRL1068, bind to highly conserved epitopes on these proteins, causing them to dissociate from the eDNA scaffold (Estelles et al., 2016, PubMed: 27324718). This dissociation leads to the rapid collapse and dispersal of the biofilm matrix across a wide range of Gram-positive and Gram-negative pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa. Once the biofilm is disrupted, the previously protected bacteria become significantly more susceptible to conventional antimicrobial therapies and clearance by the host immune system, offering a potential solution for recalcitrant infections in conditions like cystic fibrosis and chronic wounds.
Disruption of the biofilm extracellular matrix by sequestering or removing DNABII proteins from extracellular DNA (eDNA) lattices, leading to the collapse of the biofilm architecture and enhanced susceptibility of the released bacteria to antibiotics and host immune clearance (Devaraj et al., 2015, PubMed: 25938842).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNABII family protein (DNABII).